改善心力衰竭心脏功能的微小RNA相关策略
MicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure.
作者信息
Zhou Huatao, Tang Weijie, Yang Jinfu, Peng Jun, Guo Jianjun, Fan Chengming
机构信息
Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Department of Pharmacology, Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
出版信息
Front Cardiovasc Med. 2021 Nov 19;8:773083. doi: 10.3389/fcvm.2021.773083. eCollection 2021.
Heart failure (HF) describes a group of manifestations caused by the failure of heart function as a pump that supports blood flow through the body. MicroRNAs (miRNAs), as one type of non-coding RNA molecule, have crucial roles in the etiology of HF. Accordingly, miRNAs related to HF may represent potential novel therapeutic targets. In this review, we first discuss the different roles of miRNAs in the development and diseases of the heart. We then outline commonly used miRNA chemical modifications and delivery systems. Further, we summarize the opportunities and challenges for HF-related miRNA therapeutics targets, and discuss the first clinical trial of an antisense drug (CDR132L) in patients with HF. Finally, we outline current and future challenges and potential new directions for miRNA-based therapeutics for HF.
心力衰竭（HF）描述了一组由心脏作为支持全身血流的泵功能衰竭所引起的表现。微小RNA（miRNA）作为一类非编码RNA分子，在HF的病因学中发挥着关键作用。因此，与HF相关的miRNA可能代表潜在的新型治疗靶点。在本综述中，我们首先讨论miRNA在心脏发育和疾病中的不同作用。然后，我们概述常用的miRNA化学修饰和递送系统。此外，我们总结了与HF相关的miRNA治疗靶点的机遇和挑战，并讨论了一种反义药物（CDR132L）在HF患者中的首次临床试验。最后，我们概述了基于miRNA的HF治疗目前和未来面临的挑战以及潜在的新方向。
Zotero 插件